These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

542 related items for PubMed ID: 15355492

  • 1. Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam.
    Murch SJ, Cox PA, Banack SA, Steele JC, Sacks OW.
    Acta Neurol Scand; 2004 Oct; 110(4):267-9. PubMed ID: 15355492
    [Abstract] [Full Text] [Related]

  • 2. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases.
    Bradley WG, Mash DC.
    Amyotroph Lateral Scler; 2009 Oct; 10 Suppl 2():7-20. PubMed ID: 19929726
    [Abstract] [Full Text] [Related]

  • 3. Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?
    Ince PG, Codd GA.
    Neuropathol Appl Neurobiol; 2005 Aug; 31(4):345-53. PubMed ID: 16008818
    [Abstract] [Full Text] [Related]

  • 4. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer's disease.
    Pablo J, Banack SA, Cox PA, Johnson TE, Papapetropoulos S, Bradley WG, Buck A, Mash DC.
    Acta Neurol Scand; 2009 Oct; 120(4):216-25. PubMed ID: 19254284
    [Abstract] [Full Text] [Related]

  • 5. Detection of the neurotoxin BMAA within cyanobacteria isolated from freshwater in China.
    Li A, Tian Z, Li J, Yu R, Banack SA, Wang Z.
    Toxicon; 2010 May; 55(5):947-53. PubMed ID: 19822166
    [Abstract] [Full Text] [Related]

  • 6. Lack of beta-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC.
    Montine TJ, Li K, Perl DP, Galasko D.
    Neurology; 2005 Sep 13; 65(5):768-9. PubMed ID: 16157919
    [Abstract] [Full Text] [Related]

  • 7. Commentary on: Return of the cycad hypothesis--does the amyotrophic lateral sclerosis/Parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?
    Cox PA, Banack S, Murch S, Sacks O.
    Neuropathol Appl Neurobiol; 2006 Dec 13; 32(6):679-82. PubMed ID: 17083482
    [No Abstract] [Full Text] [Related]

  • 8. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm.
    Papapetropoulos S.
    Neurochem Int; 2007 Jun 13; 50(7-8):998-1003. PubMed ID: 17296249
    [Abstract] [Full Text] [Related]

  • 9. Animal models of BMAA neurotoxicity: a critical review.
    Karamyan VT, Speth RC.
    Life Sci; 2008 Jan 30; 82(5-6):233-46. PubMed ID: 18191417
    [Abstract] [Full Text] [Related]

  • 10. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.
    Cox PA, Banack SA, Murch SJ.
    Proc Natl Acad Sci U S A; 2003 Nov 11; 100(23):13380-3. PubMed ID: 14612559
    [Abstract] [Full Text] [Related]

  • 11. Creating a Simian Model of Guam ALS/PDC Which Reflects Chamorro Lifetime BMAA Exposures.
    Banack SA, Cox PA.
    Neurotox Res; 2018 Jan 11; 33(1):24-32. PubMed ID: 28478528
    [Abstract] [Full Text] [Related]

  • 12. Beta-methylamino-alanine (BMAA) injures hippocampal neurons in vivo.
    Buenz EJ, Howe CL.
    Neurotoxicology; 2007 May 11; 28(3):702-4. PubMed ID: 17379313
    [Abstract] [Full Text] [Related]

  • 13. Distinguishing the cyanobacterial neurotoxin beta-N-methylamino-L-alanine (BMAA) from its structural isomer 2,4-diaminobutyric acid (2,4-DAB).
    Banack SA, Downing TG, Spácil Z, Purdie EL, Metcalf JS, Downing S, Esterhuizen M, Codd GA, Cox PA.
    Toxicon; 2010 Nov 11; 56(6):868-79. PubMed ID: 20561540
    [Abstract] [Full Text] [Related]

  • 14. Content of the neurotoxins cycasin (methylazoxymethanol beta-D-glucoside) and BMAA (beta-N-methylamino-L-alanine) in cycad flour prepared by Guam Chamorros.
    Kisby GE, Ellison M, Spencer PS.
    Neurology; 1992 Jul 11; 42(7):1336-40. PubMed ID: 1620343
    [Abstract] [Full Text] [Related]

  • 15. Detection of cyanobacterial neurotoxin β-N-methylamino-l-alanine within shellfish in the diet of an ALS patient in Florida.
    Banack SA, Metcalf JS, Bradley WG, Cox PA.
    Toxicon; 2014 Nov 11; 90():167-73. PubMed ID: 25123936
    [Abstract] [Full Text] [Related]

  • 16. Overview of the potent cyanobacterial neurotoxin β-methylamino-L-alanine (BMAA) and its analytical determination.
    Porojan C, Mitrovic SM, Yeo DC, Furey A.
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2016 Oct 11; 33(10):1570-1586. PubMed ID: 27652898
    [Abstract] [Full Text] [Related]

  • 17. Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia.
    Sundar PD, Yu CE, Sieh W, Steinbart E, Garruto RM, Oyanagi K, Craig UK, Bird TD, Wijsman EM, Galasko DR, Schellenberg GD.
    Hum Mol Genet; 2007 Feb 01; 16(3):295-306. PubMed ID: 17185385
    [Abstract] [Full Text] [Related]

  • 18. beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-).
    Liu X, Rush T, Zapata J, Lobner D.
    Exp Neurol; 2009 Jun 01; 217(2):429-33. PubMed ID: 19374900
    [Abstract] [Full Text] [Related]

  • 19. A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.
    Chernoff N, Hill DJ, Diggs DL, Faison BD, Francis BM, Lang JR, Larue MM, Le TT, Loftin KA, Lugo JN, Schmid JE, Winnik WM.
    J Toxicol Environ Health B Crit Rev; 2017 Jun 01; 20(4):1-47. PubMed ID: 28598725
    [Abstract] [Full Text] [Related]

  • 20. The ALS/PDC syndrome of Guam and the cycad hypothesis.
    Bradley WG, Banack SA, Cox PA.
    Neurology; 2009 Feb 03; 72(5):473-4, 476; author reply 475-6. PubMed ID: 19195084
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.